Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration of MK-0431 and metformin vs monotherapy in type 2 diabetes mellitus
2005-000407-34Phase 3Completed
- Sponsor
- MSD
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-0431 + metformin, MK-0431 monotherapy and Metformin monotherapy (3 arms). Primary endpoints: HbA1c change at 24 weeks: MK-0431 + metformin vs metformin monotherapy, HbA1c change at 24 weeks: MK-0431 + metformin vs MK-0431 monotherapy and 1 more. Started Feb 2005; status: completed.
02
Drugs
sitagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-000407-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000407-34.